These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 30381394)

  • 1. Lack of evidence for substrate channeling or flux between wildtype and mutant isocitrate dehydrogenase to produce the oncometabolite 2-hydroxyglutarate.
    Dexter JP; Ward PS; Dasgupta T; Hosios AM; Gunawardena J; Vander Heiden MG
    J Biol Chem; 2018 Dec; 293(52):20051-20061. PubMed ID: 30381394
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low pH Facilitates Heterodimerization of Mutant Isocitrate Dehydrogenase IDH1-R132H and Promotes Production of 2-Hydroxyglutarate.
    Sesanto R; Kuehn JF; Barber DL; White KA
    Biochemistry; 2021 Jun; 60(25):1983-1994. PubMed ID: 34143606
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of a novel inactivating mutation in Isocitrate Dehydrogenase 1 (IDH1-R314C) in a high grade astrocytoma.
    van Lith SA; Navis AC; Lenting K; Verrijp K; Schepens JT; Hendriks WJ; Schubert NA; Venselaar H; Wevers RA; van Rooij A; Wesseling P; Molenaar RJ; van Noorden CJ; Pusch S; Tops B; Leenders WP
    Sci Rep; 2016 Jul; 6():30486. PubMed ID: 27460417
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification and Characterization of Small-Molecule Inhibitors of the R132H/R132H Mutant Isocitrate Dehydrogenase 1 Homodimer and R132H/Wild-Type Heterodimer.
    Brooks E; Wu X; Hanel A; Nguyen S; Wang J; Zhang JH; Harrison A; Zhang W
    J Biomol Screen; 2014 Sep; 19(8):1193-200. PubMed ID: 24980596
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biochemical, cellular, and biophysical characterization of a potent inhibitor of mutant isocitrate dehydrogenase IDH1.
    Davis MI; Gross S; Shen M; Straley KS; Pragani R; Lea WA; Popovici-Muller J; DeLaBarre B; Artin E; Thorne N; Auld DS; Li Z; Dang L; Boxer MB; Simeonov A
    J Biol Chem; 2014 May; 289(20):13717-25. PubMed ID: 24668804
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mutant and Wild-Type Isocitrate Dehydrogenase 1 Share Enhancing Mechanisms Involving Distinct Tyrosine Kinase Cascades in Cancer.
    Chen D; Xia S; Wang M; Lin R; Li Y; Mao H; Aguiar M; Famulare CA; Shih AH; Brennan CW; Gao X; Pan Y; Liu S; Fan J; Jin L; Song L; Zhou A; Mukherjee J; Pieper RO; Mishra A; Peng J; Arellano M; Blum WG; Lonial S; Boggon TJ; Levine RL; Chen J
    Cancer Discov; 2019 Jun; 9(6):756-777. PubMed ID: 30862724
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The potential for isocitrate dehydrogenase mutations to produce 2-hydroxyglutarate depends on allele specificity and subcellular compartmentalization.
    Ward PS; Lu C; Cross JR; Abdel-Wahab O; Levine RL; Schwartz GK; Thompson CB
    J Biol Chem; 2013 Feb; 288(6):3804-15. PubMed ID: 23264629
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular mechanisms of isocitrate dehydrogenase 1 (IDH1) mutations identified in tumors: The role of size and hydrophobicity at residue 132 on catalytic efficiency.
    Avellaneda Matteo D; Grunseth AJ; Gonzalez ER; Anselmo SL; Kennedy MA; Moman P; Scott DA; Hoang A; Sohl CD
    J Biol Chem; 2017 May; 292(19):7971-7983. PubMed ID: 28330869
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of a Novel Chemical Scaffold Against Mutant Isocitrate Dehydrogenase 1 (IDH1).
    Kang CH; Choi SU; Son YH; Lee HK; Jeong HG; Yun CS; Ahn S; Park CH
    Anticancer Res; 2020 Sep; 40(9):4929-4935. PubMed ID: 32878781
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cancer-associated isocitrate dehydrogenase mutations inactivate NADPH-dependent reductive carboxylation.
    Leonardi R; Subramanian C; Jackowski S; Rock CO
    J Biol Chem; 2012 Apr; 287(18):14615-20. PubMed ID: 22442146
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mutant IDH1 enhances the production of 2-hydroxyglutarate due to its kinetic mechanism.
    Rendina AR; Pietrak B; Smallwood A; Zhao H; Qi H; Quinn C; Adams ND; Concha N; Duraiswami C; Thrall SH; Sweitzer S; Schwartz B
    Biochemistry; 2013 Jul; 52(26):4563-77. PubMed ID: 23731180
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quantitative metabolome analysis profiles activation of glutaminolysis in glioma with IDH1 mutation.
    Ohka F; Ito M; Ranjit M; Senga T; Motomura A; Motomura K; Saito K; Kato K; Kato Y; Wakabayashi T; Soga T; Natsume A
    Tumour Biol; 2014 Jun; 35(6):5911-20. PubMed ID: 24590270
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel Insights for Inhibiting Mutant Heterodimer IDH1
    Juritz EI; Bascur JP; Almonacid DE; González-Nilo FD
    Mol Diagn Ther; 2018 Jun; 22(3):369-380. PubMed ID: 29651790
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mutant IDH1 Differently Affects Redox State and Metabolism in Glial Cells of Normal and Tumor Origin.
    Biedermann J; Preussler M; Conde M; Peitzsch M; Richter S; Wiedemuth R; Abou-El-Ardat K; Krüger A; Meinhardt M; Schackert G; Leenders WP; Herold-Mende C; Niclou SP; Bjerkvig R; Eisenhofer G; Temme A; Seifert M; Kunz-Schughart LA; Schröck E; Klink B
    Cancers (Basel); 2019 Dec; 11(12):. PubMed ID: 31888244
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased mitochondrial activity in a novel IDH1-R132H mutant human oligodendroglioma xenograft model: in situ detection of 2-HG and α-KG.
    Navis AC; Niclou SP; Fack F; Stieber D; van Lith S; Verrijp K; Wright A; Stauber J; Tops B; Otte-Holler I; Wevers RA; van Rooij A; Pusch S; von Deimling A; Tigchelaar W; van Noorden CJ; Wesseling P; Leenders WP
    Acta Neuropathol Commun; 2013 May; 1():18. PubMed ID: 24252742
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Isocitrate dehydrogenase (IDH) mutations promote a reversible ZEB1/microRNA (miR)-200-dependent epithelial-mesenchymal transition (EMT).
    Grassian AR; Lin F; Barrett R; Liu Y; Jiang W; Korpal M; Astley H; Gitterman D; Henley T; Howes R; Levell J; Korn JM; Pagliarini R
    J Biol Chem; 2012 Dec; 287(50):42180-94. PubMed ID: 23038259
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations.
    Gross S; Cairns RA; Minden MD; Driggers EM; Bittinger MA; Jang HG; Sasaki M; Jin S; Schenkein DP; Su SM; Dang L; Fantin VR; Mak TW
    J Exp Med; 2010 Feb; 207(2):339-44. PubMed ID: 20142433
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oncogenic R132 IDH1 Mutations Limit NADPH for De Novo Lipogenesis through (D)2-Hydroxyglutarate Production in Fibrosarcoma Sells.
    Badur MG; Muthusamy T; Parker SJ; Ma S; McBrayer SK; Cordes T; Magana JH; Guan KL; Metallo CM
    Cell Rep; 2018 Oct; 25(4):1018-1026.e4. PubMed ID: 30355481
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TOF-SIMS analysis of an isocitrate dehydrogenase 1 mutation-associated oncometabolite in cancer cells.
    Park J; Na HK; Shon HK; Son HY; Huh YM; Lee SW; Lee TG
    Biointerphases; 2018 Jan; 13(3):03B404. PubMed ID: 29382206
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metabolomic comparison between cells over-expressing isocitrate dehydrogenase 1 and 2 mutants and the effects of an inhibitor on the metabolism.
    Wen H; Cho HR; Yun T; Kim H; Park CK; Lee SH; Choi SH; Park S
    J Neurochem; 2015 Jan; 132(2):183-93. PubMed ID: 25251602
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.